Mesleh MF, Cross JB, Zhang J, et al. Fragment-based discovery of DNA gyrase inhibitors targeting the ATPase subunit of GyrB. Bioorg Med Chem Lett. 2016;26(4):1314-1318.
Yin N, Li J, He Y, et al. Structure–activity relationship studies of a series of semi-synthetic lipopeptides leading to the discovery of surotomycin, a novel cyclic lipopeptide being developed for the treatment of Clostridium difficile-associated diarrhea. J Med Chem. 2015;58(12):5137-5142.
Mesleh MF, Shirley WA, Heise CE, et al. NMR structural characterization of a minimal peptide antagonist bound to the extracellular domain of the corticotropin-releasing factor1 receptor. J Biol Chem. 2007;282(9):6338-6346.
Betz SF, Lio FM, Gao Y, et al. Determination of the binding mode of thienopyrimidinedione antagonists to the human gonadotropin releasing hormone receptor using compound SAR, site-directed mutagenesis, and homology modeling. J Med Chem. 2006;49(21):6170-6176.
Mesleh MF, Lee S, Veglia G, et al. Dipolar waves map the structure and topology of helices in membrane proteins. J Am Chem Soc. 2003;125(29): 8928-8935.
Michael Mesleh, Ph.D.
Michael Mesleh is a senior group leader of the biophysics team in the Center for the Development of Therapeutics (CDoT) at the Broad Institute of MIT and Harvard under the direction of Martin Drysdale. In collaboration with various groups, Mesleh is responsible for designing and leading fragment-based lead discovery and structure-based design projects. His research interests are in developing methodologies to address unmet challenges in drug discovery such as membrane proteins, biomolecular assemblies, dynamic proteins, protein-protein interfaces, and intact cells.
Prior to joining the Broad Institute in 2015, Mesleh started his career in structural chemistry at Neurocrine Biosciences and Arena Pharmaceuticals, where he contributed to several drug discovery and development programs focused on GPCRs. He later joined the Discovery Technologies group at Cubist Pharmaceuticals, where he was responsible for initiating Nuclear Magnetic Resonance (NMR)-based approaches to the discovery of new antibacterials (including fragment-based lead discovery and metabolomics) and co-led the exploratory research group. During his career he has utilized his expertise in NMR spectroscopy to identify, validate, and optimize ligands for various drug targets. He has also contributed to clinical programs for lorcaserin, nelotanserin, temanogrel, daptomycin, and surotomycin.
Mesleh holds a B.A. from the Integrated Science Program at Northwestern University, a M.Sc. in chemistry from the University of Pennsylvania, and a Ph.D. in biochemistry from University of California, San Diego. As an undergraduate he was awarded the Charles D. Hurd Scholarship and the Hypercube Scholarship in Theoretical Chemistry.
Contact Michael Mesleh via email at email@example.com.